Lilly Phase 3b updates on Taltz and Zepbound
Lilly (LLY) released new Phase 3b data on Taltz (ixekizumab) and Zepbound (tirzepatide), describing results that advance understanding of interconnected immune and metabolic biology in adults with psoriasis and obesity.